Clinical Trials

112 enrolled

Carcinoma, Non-Small-Cell Lung

NCT00708448 2025-02-13

Early Prediction of Therapeutic Response to Targeted Therapy in Stage IIIB/IV or Recurrent Lung Cancer Patients

Phase 1 Completed

26 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT06728865 2024-12-11

Better Brain

70 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT04973293 2024-11-19

Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung Cancer

Phase NA Recruiting

20 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05807893 2024-11-13

SUPER BRAIN

Phase 2/3 Completed

40 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT05468242 2024-10-30

Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy

116 enrolled

Carcinoma, Non-Small-Cell Lung

NCT00309998 2024-10-29

Vinorelbine and Bevacizumab in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

50 enrolled

Phase 2 Not yet recruiting

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06537297 2024-09-20

Intrathecal Pemetrexed Combined With High-dose Furmonertinib and Beva for EGFR-m NSCLC With Leptomeningeal Metastases

30 enrolled

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05491811 2024-09-19

EAGLE

49 enrolled

Phase EARLY_PHASE1 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06557096 2024-08-16

CSF CTC-Capture-Guided EGFR-TKI and Bevacizumab Combination Therapy in EGFR-Mutant Advanced NSCLC

100 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplastic Cells, Circulating

NCT00998166 2024-07-30

A Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy

Phase 2 Terminated

12 enrolled 3 charts

Carcinoma, Non-Small-Cell Lung

NCT06492421 2024-07-09

Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.

90 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05284539 2024-06-07

Awesome

760 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04322578 2024-06-04

CONFIRM

120 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04238169 2024-02-28

Clinical Trial Assessing the Efficacy of Abscopal Effect Induced by SBRT and Immunotherapy in Advanced NSCLC

60 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05296278 2024-01-10

Efficacy and Biomarker Explanation of IBI-323 + Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC

70 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03647592 2023-12-27

Real World Study on Erlotinib/Gefitinib Combined With Bevacizumab in Advanced Non-aquamous Non-small Cell Lung Cancer

Unknown

30 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06182800 2023-12-27

Adebrelimab Combined With Bevacizumab and Docetaxel for Advanced Non-Squamous Non-small Cell Lung Cancer After Progression on First-line Immunotherapy

35 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04099836 2023-12-26

Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib

Phase 2 Terminated

7 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT02803203 2023-09-22

Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers

Phase 1/2 Completed

49 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT04345146 2023-08-28

Bevacizumab Combined With Fractionated Stereotactic Radiotherapy for 1 to 10 Brain Metastases From NSCLC

100 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT03991403 2023-04-03

Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC

Phase 3 Unknown

228 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04974879 2023-03-29

Osimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Metastatic Non-Small Cell Lung Cancer

20 enrolled

Bronchial Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT05104281 2023-03-29

Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer

Phase 3 Unknown

60 enrolled

Bronchial Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT01705184 2023-03-13

BUCiL

120 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05754736 2023-03-06

Clinical Study of Ametinib Combined With Bevacizumab in First-line Treatment of Advanced NSCLC With EGFR-mutations.

50 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03713944 2023-03-01

Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer

Phase 2 Terminated

30 enrolled 28 charts

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT05738317 2023-02-22

Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel in Non-squamous NSCLC After First-line Treatment

45 enrolled

Carcinoma, Non-Small-Cell Lung

NCT01649947 2022-11-21

Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II

32 enrolled 9 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00970684 2022-08-16

Bevacizumab, Docetaxel, and Gemcitabine Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

13 enrolled 9 charts

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05273814 2022-07-13

Study of Chemotherapy and PD-1 Inhibitor Combination With Anti-angiogenesis to Treat Elderly Lung Cancer

Phase 1 Unknown

30 enrolled

Carcinoma, Non-Small-Cell Lung

NCT00553800 2022-07-12

NSCLC

32 enrolled 8 charts

Carcinoma, Non-Small-Cell Lung

NCT00456261 2022-05-03

First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC

110 enrolled 8 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02743923 2021-12-21

Cisplatin-Pemetrexed Compared With Carboplatin-Paclitaxel-Bevacizumab in KRAS Mutated Non-small Cell Lung Cancer

Phase 3 Unknown

203 enrolled